Annie Kathleen Brown

Annie Kathleen Brown

Auto-generated profile, based on publicly available information

Annie Kathleen Brown

Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, California

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
NDNatalie Duong
Natalie Duong
KCKevin Curley
Kevin Curley
ABAnnie Brown
Annie Brown
ACAlexander Campanelli
Alexander Campanelli
MDMai Anh Do
Mai Anh Do
Biao LuBiao Lu
Biao Lu
Background: Exosomes are ubiquitous naturally secreted stable nanovesicles that can be engineered to target and deliver novel therapeutics to treat a host of human diseases. Methods: We engineered the surfaces of cell-derived nanovesicles to act as decoys in the treatment of inflammation by antagonizing the major proinflammatory cytokine, tumor necrosis factor alpha (TNFα). Results: Decoy exosomes were generated by displaying the TNFα binding domain of human TNF receptor-1 (hTNFR1) on the outer surface of exosomes using stably transfected HEK293 cells. We developed an efficient method to purify the engineered exosomes from conditioned medium based on sequential centrifugation, ultrafiltration, and precipitation. We characterized decoy exosomes using immune-quantification, nanoparticle tracking analysis, and confocal microscopy to confirm that they retain the correct orientation, size, and shape of naturally produced exosomes. We demonstrated the engineered decoy exosomes specifically antagonize activities of TNFα using an inflammatory reporter cell line. Conclusions: Decoy exosomes produced in human cells serve as a novel biologic reagent for antagonizing inflammatory signaling mediated by TNFα.

7 January 2025 in Cancer Discovery
Verified
Journal Article
Closed access
YSYi Jiun Su
Yi Jiun Su
AKAnne Marijn Kramer
Anne Marijn Kramer
MHMark P. Hamilton
Mark P. Hamilton
NANeha Agarwal
Neha Agarwal
HSHrishikesh K. Srinagesh
Hrishikesh K. Srinagesh
MFMatthew J. Frank
Matthew J. Frank
Patients with large B-cell lymphoma that progresses after anti–CD19 chimeric antigen receptor (CAR) T-cell (CAR19) therapy have poor outcomes. Subsequent CAR T-cell therapy shows promise, but the impact of residual CAR19 and early relapse remains unclear. We evaluated 37 patients with CAR19-refractory large B-cell lymphoma who received anti–CD22 CAR T-cell (CAR22) in a phase Ib trial (NCT04088890). Residual CAR19 was unquantifiable in 17 of 33 evaluable patients post-CAR22 infusion. Single-cell RNA sequencing revealed minimal CAR19/CAR22 co-transduction. Peak CAR19 transgene levels did not affect CAR22 efficacy or toxicities. CAR22 products from patients undergoing leukapheresis ≥6 months after CAR19 had higher CD4+ naïve T and CD4+/CD8+ T central memory (TCM) cells, with lower CD4+ T effector memory (TEM) cells. High and low percentages of CAR22 TCM and TEM, respectively, were correlated with CAR22 transduction efficiency and complete response. Residual CAR19 and leukapheresis timing did not significantly affect outcomes, whereas CAR22 product composition was significantly correlated with treatment response. Significance: Late leukapheresis (>6 months after CAR19) resulted in less residual CAR19, higher CAR22 CD4+ naïve T and TCM cells, less TEM cells, and higher CD8+ TCM cells, but similar clinical outcomes to those with early leukapheresis. CAR22 responses were associated with higher transduction efficiency and CD8+ TCM and less CD8+ TEM cells.

17 June 2026
Verified
Other
Open access
PDF file
YSYi Jiun Su
Yi Jiun Su
AKAnne Marijn Kramer
Anne Marijn Kramer
MHMark P. Hamilton
Mark P. Hamilton
NANeha Agarwal
Neha Agarwal
HSHrishikesh K. Srinagesh
Hrishikesh K. Srinagesh
MFMatthew J. Frank
Matthew J. Frank
Comparative analysis of Comparative analysis of T cell subsets of CD4/CD8 enrichment material during CAR22 manufacturing process. (A) CD4+ and (B) CD8+ T cells.

17 June 2026
Verified
Other
Open access
YSYi Jiun Su
Yi Jiun Su
AKAnne Marijn Kramer
Anne Marijn Kramer
MHMark P. Hamilton
Mark P. Hamilton
NANeha Agarwal
Neha Agarwal
HSHrishikesh K. Srinagesh
Hrishikesh K. Srinagesh
MFMatthew J. Frank
Matthew J. Frank
Linear regression analysis of CAR22 transduction efficiency, vector copy number (VCN) and T cell subsets in CD4/CD8 enrichment material and CAR22 product (A) Linear regression of CAR22 transduction efficiency versus T cell subsets in CD4/CD8 enrichment material. (B) Linear regression of CAR22 transduction efficiency versus T cell subsets in the products. (C) Linear regression of CAR22 VCN versus T cell subsets in CD4/CD8 enrichment material. (D) Linear regression of CAR22 VCN versus T cell subsets in the products.


2 April 2025
Verified
Other
Open access
YSYi Jiun Su
Yi Jiun Su
AKAnne Marijn Kramer
Anne Marijn Kramer
MHMark P. Hamilton
Mark P. Hamilton
NANeha Agarwal
Neha Agarwal
HSHrishikesh K. Srinagesh
Hrishikesh K. Srinagesh
MFMatthew J. Frank
Matthew J. Frank
Quantifiable CAR19 transgene levels in leukapheresis material and CAR22 products, and their correlation with CAR22 complete response (CR) rate and survival outcomes. (A) The CR rate is similar between patients with and without quantifiable CAR19 transgene levels in leukapheresis material and CAR22 products. (B) Progression-free survival (PFS) and overall survival (OS) are similar between patients with and without quantifiable CAR19 transgene levels in leukapheresis material. (C) PFS and OS are similar between patients with and without quantifiable CAR19 transgene levels in CAR22 products.